Renaissance Technologies’s Unity Biotechnology UBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-98,311
Closed -$37.8K 3942
2025
Q2
$37.8K Buy
98,311
+4,100
+4% +$3.51K ﹤0.01% 3423
2025
Q1
$98K Buy
94,211
+17,300
+22% +$31.2K ﹤0.01% 3201
2024
Q4
$75.1K Sell
76,911
-16,759
-18% -$20.8K ﹤0.01% 3326
2024
Q3
$138K Buy
93,670
+29,088
+45% +$42.7K ﹤0.01% 3201
2024
Q2
$87.2K Sell
64,582
-42,359
-40% -$64.3K ﹤0.01% 3208
2024
Q1
$175K Buy
106,941
+68,770
+180% +$119K ﹤0.01% 3258
2023
Q4
$74K Sell
38,171
-200
-0.5% -$372 ﹤0.01% 3378
2023
Q3
$92K Sell
38,371
-4,100
-10% -$10.9K ﹤0.01% 3268
2023
Q2
$108K Sell
42,471
-35,000
-45% -$92.4K ﹤0.01% 3453
2023
Q1
$126K Sell
77,471
-13,700
-15% -$54.9K ﹤0.01% 3420
2022
Q4
$250K Sell
91,171
-67,066
-42% -$195K ﹤0.01% 3319
2022
Q3
$625K Buy
158,237
+62,465
+65% +$394K ﹤0.01% 2789
2022
Q2
$540K Buy
95,772
+5,100
+6% +$42.5K ﹤0.01% 3122
2022
Q1
$1.02M Sell
90,672
-17,098
-16% -$192K ﹤0.01% 2719
2021
Q4
$1.57M Buy
107,770
+43,700
+68% +$955K ﹤0.01% 2341
2021
Q3
$1.92M Buy
64,070
+12,810
+25% +$452K ﹤0.01% 2121
2021
Q2
$2.38M Buy
+51,260
New +$2.47M ﹤0.01% 2145
2020
Q3
Sell
-28,090
Closed -$2.44M 3697
2020
Q2
$2.44M Buy
28,090
+13,650
+95% +$1.01M ﹤0.01% 2083
2020
Q1
$838K Buy
14,440
+11,440
+381% +$721K ﹤0.01% 2509
2019
Q4
$216K Buy
+3,000
New +$212K ﹤0.01% 3178

Other funds holding UBX

Renaissance Technologies's UBX Position: Q3 2025 in Review

Renaissance Technologies sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 98,311 shares — an estimated $37.8K sold.

Renaissance Technologies first reported a position in UBX in Q4 2019 and held it in 20 quarters. The position peaked at $2.44M in Q2 2020. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Renaissance Technologies reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Renaissance Technologies sold 98,311 Unity Biotechnology shares in Q3 2025, an estimated $37.8K.
  • Renaissance Technologies first reported a position in Unity Biotechnology in Q4 2019 and held it in 20 quarters.
  • Renaissance Technologies's Unity Biotechnology position peaked at $2.44M in Q2 2020.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.